CD247 and myelodysplastic syndrome: In a phase I clinical trial study conducted by Baumeiste et al. [145], autologous first-generation NKG2D-CD3ζ-CAR T cell was engineered and validated in AML and myelodysplastic syndrome (MDS) patients.